Search - tctmd.com

Displaying 61 - 80 of 119

Sort: Relevancy | Date

News Industry News

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

October 12, 2015

News Industry News

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

October 12, 2015

News Industry News

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Industry News

Boston Scientific Announces Scheduled Presentations At TCT 2015

October 08, 2015

News Industry News

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

October 07, 2015

News Industry News

REVA Completes Clinical Enrollment Milestone

October 01, 2015

News Industry News

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

September 01, 2015

News Daily News

TAVR 术后中度至重度二尖瓣关闭不全提示死亡风险上升

Todd Neale

June 18, 2015

News Daily News

Moderate-to-Severe Mitral Regurgitation Signals Elevated Mortality Risk After TAVR

Todd Neale

June 18, 2015

News Daily News

La Regurgitación Mitral Moderada-Severa Señala un Mayor Riesgo de Mortalidad Post-TAVR

Todd Neale

June 18, 2015

News Daily News

一个比利时登记处的报告显示，在经股动脉TAVR中采取Sapien、CoreValve时的3年生存率结果相似

Yael L. Maxwell

June 03, 2015

News Daily News

Un Registro Belga Confirma una Supervivencia Similar a los 3 Años con las Válvulas Sapien y CoreValve en la realización de TAVR Transfemorales

Yael L. Maxwell

June 03, 2015

News Daily News

Belgian Registry Reports Similar 3-Year Survival for Sapien, CoreValve in Transfemoral TAVR

Yael L. Maxwell

June 03, 2015

News Daily News

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

L.A. McKeown

February 26, 2015

News Daily News

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

December 14, 2014

News Daily News

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

L.A. McKeown

September 02, 2014

Advertisement

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

Boston Scientific Announces Scheduled Presentations At TCT 2015

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

REVA Completes Clinical Enrollment Milestone

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

TAVR 术后中度至重度二尖瓣关闭不全提示死亡风险上升

Moderate-to-Severe Mitral Regurgitation Signals Elevated Mortality Risk After TAVR

La Regurgitación Mitral Moderada-Severa Señala un Mayor Riesgo de Mortalidad Post-TAVR

一个比利时登记处的报告显示，在经股动脉TAVR中采取Sapien、CoreValve时的3年生存率结果相似

Un Registro Belga Confirma una Supervivencia Similar a los 3 Años con las Válvulas Sapien y CoreValve en la realización de TAVR Transfemorales

Belgian Registry Reports Similar 3-Year Survival for Sapien, CoreValve in Transfemoral TAVR

EVERBIO II Published: BVS Matches Leading DES for Midterm Outcomes

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

PROTECT: Lower Stent Thrombosis Risk with Endeavor Emerges at 4 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content